Cladribine, Low-Dose Cytarabine (LDAC), and Venetoclax (VEN) in Older/Unfit Acute Myeloid Leukemia (AML) Patients: A Single-Institution Experience

被引：0
|
作者：
Yohannan, Binoy [1 ]
Khan, Hina [1 ]
Cervoni-Curet, Frances [1 ]
Rios, Adan [1 ]
机构：
[1] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
AML; cladribine; low-dose cytarabine; older/unfit AML;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-100
引用
收藏
页码：S267 / S267
页数：1
相关论文
共 50 条
  • [21] Single-institution experience of venetoclax combined with azacitidine in newly diagnosed acute myeloid leukemia patients
    Yu, Hong
    Wang, Chaomeng
    Lei, Yingying
    Li, Lijuan
    Wang, Huaquan
    Wang, Guojin
    Xing, Limin
    Guan, Jing
    Song, Jia
    Wu, Yuhong
    Liu, Hong
    Qu, Wen
    Wang, Xiaoming
    Shao, Zonghong
    Fu, Rong
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 127
  • [22] OVERALL SURVIVAL (OS) AND CLINICAL OUTCOMES IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH AZACITIDINE (AZA) OR LOW-DOSE CYTARABINE (LDAC) IN THE AZA-AML-001 STUDY
    Seymour, J. F.
    Doehner, H.
    Kumar, R.
    Stone, R. M.
    Wierzbowska, A.
    Bernal del Castillo, T.
    Falantes, J.
    Delaunay, J.
    Sabloff, M.
    Voso, M. T.
    Kim, I.
    Ram, R.
    Gau, J. P.
    Songer, S.
    Lucy, L. M.
    Beach, C.
    Dombret, H.
    HAEMATOLOGICA, 2015, 100 : 381 - 381
  • [23] Results of omacetaxine plus low-dose cytarabine (LD-araC) in older patients with acute myeloid leukemia (AML).
    Kadia, Tapan M.
    Daver, Naval Guastad
    Ravandi, Farhad
    Jabbour, Elias
    Pemmaraju, Naveen
    Pierce, Sherry
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
    Kadia, Tapan M.
    Reville, Patrick K.
    Wang, Xuemei
    Rausch, Caitlin R.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval G. G.
    DiNardo, Courtney D. D.
    Sasaki, Koji
    Issa, Ghayas C. C.
    Ohanian, Maro
    Montalban-Bravo, Guillermo
    Short, Nicholas J. J.
    Jain, Nitin
    Ferrajoli, Alessandra
    Bhalla, Kapil N. N.
    Jabbour, Elias
    Takahashi, Koichi
    Malla, Rashmi
    Quagliato, Kelly
    Kanagal-Shamanna, Rashmi
    Popat, Uday R. R.
    Andreeff, Michael
    Garcia-Manero, Guillermo
    Konopleva, Marina Y. Y.
    Ravandi, Farhad
    Kantarjian, Hagop M. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (33) : 3848 - +
  • [25] Combination Treatment of Venetoclax and Hypomethylating Agents (HMA) or Low-Dose Cytarabine (LDAC) for Patients with Acute Myeloid Leukemia (AML) - Real-World Data from Two German Academic Centers
    Schmalbrock, Laura K.
    Braitsch, Krischan
    Jung, Paul
    Bumeder, Irmgard
    Kiewe, Philipp
    Westermann, Joerg
    Bullinger, Lars
    Keller, Ulrich
    Bassermann, Florian
    Kroenke, Jan
    Rieger, Kathrin
    Goetze, Katharina S.
    BLOOD, 2021, 138
  • [26] Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients
    Andrius Zucenka
    Kazimieras Maneikis
    Birute Pugaciute
    Ugne Ringeleviciute
    Austeja Dapkeviciute
    Linas Davainis
    Guoda Daukelaite
    Paulina Burzdikaite
    Vytautas Staras
    Laimonas Griskevicius
    Annals of Hematology, 2021, 100 : 1195 - 1202
  • [27] Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients
    Zucenka, Andrius
    Maneikis, Kazimieras
    Pugaciute, Birute
    Ringeleviciute, Ugne
    Dapkeviciute, Austeja
    Davainis, Linas
    Daukelaite, Guoda
    Burzdikaite, Paulina
    Staras, Vytautas
    Griskevicius, Laimonas
    ANNALS OF HEMATOLOGY, 2021, 100 (05) : 1195 - 1202
  • [28] Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience
    Piccini, Matteo
    Pilerci, Sofia
    Scappini, Barbara
    Mannelli, Francesco
    Ciolli, Gaia
    Pasquini, Andrea
    Fasano, Laura
    Quinti, Elisa
    Guglielmelli, Paola
    Mannarelli, Carmela
    Pancani, Fabiana
    Zizza, Michela
    Signori, Leonardo
    Vannucchi, Alessandro M.
    Gianfaldoni, Giacomo
    BLOOD, 2022, 140 : 9008 - 9009
  • [29] An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia
    Othman, Tamer A.
    Tenold, Matthew E.
    Moskoff, Benjamin N.
    Azenkot, Tali
    Jonas, Brian A.
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (05) : 407 - 417
  • [30] Comparative effectiveness of glasdegib versus venetoclax combined with low-dose cytarabine in acute myeloid leukemia
    Tremblay, Gabriel
    Daniele, Patrick
    Bell, Timothy
    Chan, Geoffrey
    Brown, Andrew
    Cappelleri, Joseph C.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (07) : 603 - 612
12345